Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 14/20 | 1.00 |
| ▸ | IGF1R | P08069 | 9/20 | 1.00 |
| ▸ | MAPK3 | P27361 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4984590 | 0.95 | MAP2K1 (0.91) | MAP2K1IGF1RMAPK3MAPK1MAP3K1 | |
| SCHEMBL4986096 | 0.92 | MAP2K1 (0.85) | MAP2K1IGF1RMAPK3MAPK1MAP3K1 | |
| SCHEMBL20247906 | 0.91 | MAP2K1 (0.83) | MAP2K1IGF1RMAPK3MAPK1MAP3K1 | |
| SCHEMBL2972917 | 0.90 | IGF1R (0.89) | MAP2K1IGF1RMAPK3MAPK1MAP3K1 | |
| SCHEMBL4447775 | 0.90 | MAP2K1 (1.00) | MAP2K1IGF1RMAPK3MAPK1MAP3K1 | |
| SCHEMBL4443456 | 0.89 | IGF1R (1.00) | MAP2K1IGF1RMAPK3MAPK1MAP3K1 | |
| SCHEMBL2969475 | 0.89 | MAP2K1 (0.88) | MAP2K1IGF1RMAPK3MAPK1MAP3K1 | |
| SCHEMBL2961308 | 0.89 | IGF1R (0.89) | MAP2K1IGF1RMAPK3MAPK1MAP3K1 | |
| SCHEMBL6183526 | 0.89 | IGF1R (0.89) | MAP2K1IGF1RMAPK3MAPK1MAP3K1 | |
| SCHEMBL6998163 | 0.88 | MAP2K1 (0.79) | MAP2K1IGF1RMAPK3MAPK1MAP3K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-03-24 | — | — | US | claimed |
| US-12146196-B2 | C-RAF mutants that confer resistance to RAF inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-11-19 | — | — | US | claimed |
| US-20240299558-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-12 | — | — | US | claimed |
| US-20240293557-A1 | PROTEOLYSIS TARGETING CHIMERAS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-09-05 | — | — | US | claimed |
| US-20240093310-A1 | C-RAF Mutants that Confer Resistance to RAF Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-03-21 | — | — | US | claimed |
| US-11788151-B2 | C-RAF mutants that confer resistance to RAF inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | claimed |
| CN-116036278-A | Compositions and methods for treating cancers with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| WO-2022266491-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-12-22 | — | — | WO | claimed |
| WO-2022261220-A1 | PROTEOLYSIS TARGETING CHIMERAS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-12-15 | — | — | WO | claimed |
| CN-110799245-B | Compositions and methods for treating cancer with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2022-08-09 | — | — | CN | claimed |
| US-20130059851-A1 | Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-07 | — | — | US | claimed |
| EP-2545187-A1 | METHODS OF DIAGNOSING AND TREATING CANCER IN PATIENTS HAVING OR DEVELOPING RESISTANCE TO A FIRST CANCER THERAPY | Dana-Farber Cancer Institute Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| US-20130004509-A1 | BRAF Mutations Conferring Resistance to BRAF Inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-01-03 | — | — | US | claimed |
| EP-2538943-A1 | BRAF MUTATIONS CONFERRING RESISTANCE TO BRAF INHIBITORS | Dana-Farber Cancer Institute, Inc. (US) | 2013-01-02 | — | — | EP | claimed |
| WO-2011112678-A1 | METHODS OF DIAGNOSING AND TREATING CANCER IN PATIENTS HAVING OR DEVELOPING RESISTANCE TO A FIRST CANCER THERAPY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| WO-2011106298-A1 | BRAF MUTATIONS CONFERRING RESISTANCE TO BRAF INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-09-01 | — | — | WO | claimed |
| EP-1117659-B1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | WYETH CORP (US) | 2003-12-03 | — | — | EP | claimed |
| US-6288082-B1 | COMPOUNDS SUCH AS 6,7-DIETHOXY-4-(INDAN-5-YLAMINO) -QUINOLINE-3-CARBONITRILE USED AS ANTINEOPLASTIC AGENTS AND IN THE TREATMENT OF POLYCYCSTIC KIDNEY DISEASE | AMERICAN CYANAMID COMPANY | 2001-09-11 | — | — | US | claimed |
| EP-1117659-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | claimed |
| WO-2000018761-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299558-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | BCL3, MCL1, BCL2 | MAP2K1 1502/4885IGF1R 2878/4885MAPK3 3685/4885 |
| US-20240293557-A1 | PROTEOLYSIS TARGETING CHIMERAS AND METHODS OF USE THEREOF | MCL1, BCL3, CRBN | MAP2K1 3050/4885IGF1R 1370/4885MAPK3 3412/4885 |
| US-20130059851-A1 | Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy | CRKL, RAF1, TPX2 | MAP2K1 53/4885IGF1R 897/4885MAPK3 698/4885 |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BRAF, SRMS, MAPK3 | MAP2K1 40/4885IGF1R 2155/4885MAPK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.